Verrica Pharmaceuticals Inc expected to post a loss of 70 cents a share - Earnings Preview

Verrica Pharmaceuticals

08/08/2025 16:22

Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 for the period ending June 30 2025

The West Chester Pennsylvania-based  company is expected to report a 17.6% decrease in revenue to $4.267 million from $5.18 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Verrica Pharmaceuticals Inc is for a loss of 70 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $40.00, about 84.7% above its last closing price of $6.11

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.05
-0.97
-1.00
Missed
-2.6
Dec. 31 2025
-2.84
-2.62
-2.40
Beat
8.6
Sep. 30 2024
-3.93
-3.67
-4.90
Missed
-33.5​
Jun. 30 2024
-4.28
-4.25
-3.70
Beat
12.9
​​Mar. 31 2024
-4.58
-3.97
-4.40
Missed
-10.9
Dec. 31 2023
-5.31
-5.28
-5.30
Missed
-0.4​
Sep. 30 2023
-3.55
-3.61
-5.40
Missed
-49.5
Jun. 30 2023
-2.21
-2.10
-2.40
Missed
-14.2

This summary was machine generated August 8 at 15:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)